A single-dose combination therapy that both prevents and treats anthrax infection

Vaccine

Volumn 27, Issue 12, 2009, Pages 1811-1815

  Klinman, Dennis M ^a   Tross, Debra ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anthrax; CpG ODN; Dalbavancin; Protection; Vaccine

Indexed keywords

ANTHRAX VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DALBAVANCIN; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEPTICEMIA; SINGLE DRUG DOSE; SPORE GERMINATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; CPG ISLANDS; INDICATORS AND REAGENTS; MICE; MICE, INBRED A; TEICOPLANIN;

EID: 61349104291     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.094     Document Type: Article

References (52)

1. Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 225 (1998) 13-35
2. Lane H.C., Montagne J.L., and Fauci A.S. Bioterrorism: a clear and present danger. Nat Med 7 December (12) (2001) 1271-1273
3. Ross J.M. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 73 (1957) 485-494
4. Henderson D.W., Peacock S., and Belton F.C. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 54 (1956) 28-36
5. Glassman H.N. Industrial inhalation anthrax: discussion. Bateriol Rev 30 (1966) 657-659
6. Occupational health guidelines for remediation workers at Bacillus anthracis-contaminated sites-United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002;51(September (35)):786-9.
7. Stern E.J., Uhde K.B., Shadomy S.V., and Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 14 April (4) (2008)
8. Meropol S.B., Chan K.A., Chen Z., Finkelstein J.A., Hennessy S., Lautenbach E., et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf 17 May (5) (2008) 523-532
9. Jefferds M.D., Laserson K., Fry A.M., Roy S., Hayslett J., Grummer-Strawn L., et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001. Emerg Infect Dis 8 October (10) (2002) 1138-1144
10. Shepard C.W., Soriano-Gabarro M., Zell E.R., Hayslett J., Lukacs S., Goldstein S., et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 8 October (10) (2002) 1124-1132
11. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 261 June (22) (1989) 3273-3277
12. Harter J.G., Peck C.C., and Chronobiology. Suggestions for integrating it into drug development. Ann NY Acad Sci 618 (1991) 563-571
13. Friedlander A.M., and Brachman P.S. Anthrax. In: Plotkin S.A., and Mortimer E.A. (Eds). Vaccines (1998), PA, W.B. Saunders, Philadelphia pp. 729-39
14. Ivins B.E., and Welkos S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4 March (1) (1988) 12-19
15. Chowdhury K., Light S.E., Garon C.F., Ito Y., and Israel M.A. A cloned polyoma DNA fragment representing the 5′ half of the early gene region is oncogenic. J Virol 36 November (2) (1980) 566-574
16. Little S.F., and Ivins B.E. Molecular pathogenesis of Bacillus anthracis infection. Microb Infect 1 February (2) (1999) 131-139
17. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 June (Pt 6) (2001) 1677-1685
18. Welkos S.L., and Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5 August (2) (1988) 127-139
19. Pittman P.R., Gibbs P.H., Cannon T.L., and Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 20 December (5-6) (2001) 972-978
20. Brachman P.S., Gold H., Plotkin S.A., Fedety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health 52 (1962) 632-645
21. Ready T. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat Med 10 February (2) (2004) 112
22. Geier D.A., and Geier M.R. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin Exp Rheumatol 20 March (2) (2002) 217-220
23. Lange J.L., Lesikar S.E., Rubertone M.V., and Brundage J.F. Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998-2000. Vaccine 21 April (15) (2003) 1620-1628
24. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 73 February (2) (2005) 828-833
25. Klinman D.M., Currie D., Lee G., Grippe V., and Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microb Infect 9 October (12-13) (2007) 1478-1483
26. Klinman D.M., Xie H., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann NY Acad Sci 1082 October (2006) 137-150
27. Krieg A.M., Yi A., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-548
28. Klinman D.M., Yi A., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc Natl Acad Sci USA 93 (1996) 2879-2883
29. Takeshita F., Leifer C.A., Gursel I., Ishii K., Takeshita S., Gursel M., et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167 7 (2001) 3555-3558
30. Hemmi H., Takeuchi O., Kawai T., Sato S., Sanjo H., Matsumoto M., et al. A toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
31. Ballas Z.D., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 (1996) 1840-1847
32. Halpern M.D., Kurlander R.J., and Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha. Cell Immunol 167 (1996) 72-78
33. Vietri N.J., Purcell B.K., Lawler J.V., Leffel E.K., Rico P., Gamble C.S., et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 103 May (20) (2006) 7813-7816
34. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., and Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47 June (6) (2003) 1968-1971
35. Streit J.M., Fritsche T.R., Sader H.S., and Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 48 February (2) (2004) 137-143
36. Leighton A., Gottlieb A.B., Dorr M.B., Jabes D., Mosconi G., VanSaders C., et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48 March (3) (2004) 940-945
37. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 July (11-12) (1998) 1141-1148
38. Ivins B.E., Welkos S.L., Knudson G.B., and Little S.F. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun 58 February (2) (1990) 303-308
39. Harvill E.T., Lee G., Grippe V.K., and Merkel T.J. Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect Immun 73 July (7) (2005) 4420-4422
40. Klinman D.M., Xie H., Little S.F., Currie D., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22 July (21-22) (2004) 2881-2886
41. Rynkiewicz D, Rathkopf M, Ransom J, et al. Marked enhancement of antibody response to anthrax vaccine adsorbed with CpG 7909 in healthy volunteers. ICAAC abstract LB-25, 2005.
42. Heine H.S., Bassett J., and Miller L. In vitro and in vivo activity of dalbavancin against Bacillus anthracis. 45th Interscience Conference on Antimicrobial agents (2005) (abstract A-1435)
43. Tross D., and Klinman D.M. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol 181 August (8) (2008) 5785-5790
44. Baillie L.W. Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 101 September (3) (2006) 594-606
45. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8 August (8) (2002) 833-841
46. Kelly C.D., O'Loughlin C., Gelder F.B., Peterson J.W., Sower L.E., and Cirino N.M. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines 5 (2007) 11
47. Vitale L., Blanset D., Lowy I., O'Neill T., Goldstein J., Little S.F., et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 74 October 10 (2006) 5840-5847
48. Herrmann J.E., Wang S., Zhang C., Panchal R.G., Bavari S., Lyons C.R., et al. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine 24 July (31-32) (2006) 5872-5880
49. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 25 May (3-4) (2006) 135-154
50. Sparwasser T., Koch E., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28 6 (1998) 2045-2054
51. Gursel M., Verthelyi D., and Klinman D.M. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 32 September (9) (2002) 2617-2622
52. Loving C.L., Kennett M., Lee G.M., Grippe V.K., and Merkel T.J. Murine aerosol challenge model of anthrax. Infect Immun 75 June (6) (2007) 2689-2698